Serveur d'exploration sur la maladie de Parkinson - Exploration (Accueil)

Index « Keywords » - entrée « neuroprotection »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
neuroplasticity < neuroprotection < neuroprotection/neurorescue  Facettes :

List of bibliographic references indexed by neuroprotection

Number of relevant bibliographic references: 39.
[0-20] [0 - 20][0 - 39][20-38][20-40]
Ident.Authors (with country if any)Title
000229 (2011) Yuen-Sum Lau [États-Unis] ; Gaurav Patki [États-Unis] ; Kaberi Das-Panja [États-Unis] ; Wei-Dong Le [États-Unis] ; S. Omar Ahmad [États-Unis]Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson’s disease with moderate neurodegeneration
000318 (2011) Peter Jenner [Royaume-Uni] ; J. William Langston [États-Unis]Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline
000370 (2011) A. H. V. Schapira [Royaume-Uni]Challenges to the development of disease‐modifying therapies in Parkinson’s disease
000379 (2011) Robert D. Altman [Canada] ; Anthony E. Lang [Canada] ; Ronald B. Postuma [Canada]Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study
000416 (2011) Anthony E. Lang [Canada]A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials
000567 (2010) Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis]Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study
000630 (2010) Xiao-Qing Tang [République populaire de Chine] ; Yu-Juan Li ; Jing Zhao ; Xing-Tian Shen ; Chun-Tao Yang ; Li-Li Fan ; Bi Hu ; Yuan-Jian Li ; Duan-Fan Liao [République populaire de Chine]Neuroprotective effect of asymmetric dimethylarginine against 1‐methyl‐4‐phenylpyridinium ion‐induced damage in PC12 cells
000731 (2010) Noriyuki Yamamoto [Japon] ; Yasuhiko Izumi [Japon] ; Takaaki Matsuo [Japon] ; Seiko Wakita [Japon] ; Toshiaki Kume [Japon] ; Yuki Takada-Takatori [Japon] ; Hideyuki Sawada [Japon] ; Akinori Akaike [Japon]Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic neuroprotection
000841 (2010) Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande]A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease
000994 (2009) A. H. Schapira [Royaume-Uni] ; Yves Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne]Perspectives on recent advances in the understanding and treatment of Parkinson’s disease
000A14 (2009) Hiroki Takeuchi [Japon] ; Takashi Yanagida [Japon] ; Masatoshi Inden [Japon] ; Kazuyuki Takata [Japon] ; Yoshihisa Kitamura [Japon] ; Kentaro Yamakawa [Japon] ; Hideyuki Sawada [Japon] ; Yasuhiko Izumi [Japon] ; Noriyuki Yamamoto [Japon] ; Takeshi Kihara [Japon] ; Kengo Uemura [Japon] ; Haruhisa Inoue [Japon] ; Takashi Taniguchi [Japon] ; Akinori Akaike [Japon] ; Ryosuke Takahashi [Japon] ; Shun Shimohama [Japon]Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone‐induced Parkinson's disease models
000A19 (2009) Robert G. Hart [États-Unis] ; Lesly A. Pearce [États-Unis] ; Bernard M. Ravina [États-Unis] ; Toby C. Yaltho [États-Unis] ; John R. Marler [États-Unis]Neuroprotection trials in Parkinson's disease: Systematic review
000A43 (2009) Robert A. Hauser [États-Unis] ; Mark F. Lew [États-Unis] ; Howard I. Hurtig [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Cheryl J. Fitzer-Attas [Israël]Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
000A73 (2009) Na K. Kim [Corée du Sud] ; Byung H. Choi [Corée du Sud] ; Xian Huang [Corée du Sud] ; Brian J. Snyder [Canada] ; Shefqat Bukhari [Canada] ; Tae-Ho Kong [Corée du Sud] ; Hyeonseon Park [Corée du Sud] ; Hyung C. Park [Corée du Sud] ; So R. Park [Corée du Sud] ; Yoon Ha [Corée du Sud]Granulocyte–macrophage colony‐stimulating factor promotes survival of dopaminergic neurons in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced murine Parkinson’s disease model
000C29 (2008) Ilana Schlesinger [Israël] ; Naomi Schlesinger [États-Unis]Uric acid in Parkinson's disease
000C50 (2008) Anthony H. V. Schapira [Royaume-Uni]The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
000C79 (2008) Genevieve Bureau [Canada] ; Fanny Longpré [Canada] ; M. Martinoli [Canada]Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation
000C96 (2008) A. H. V. Schapira [Royaume-Uni]Progress in neuroprotection in Parkinson’s disease
000D31 (2008) Maryka Quik [États-Unis] ; Kathryn O'Leary [États-Unis] ; Caroline M. Tanner [États-Unis]Nicotine and Parkinson's disease: Implications for therapy
000E64 (2008) Carl E. Clarke [Royaume-Uni]Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
000E78 (2008) C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "neuroprotection" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "neuroprotection" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    neuroprotection
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024